Activ Surgical Granted U.S. Patent for ActivSight Enhanced Visualization Module

Activ Surgical Granted U.S. Patent for ActivSight Enhanced Visualization Module

Activ Surgical's patent-protected surgical software platform reduces unintended and preventable surgical complications by enhancing a surgeon's intra-operative decision-making.

FREMONT, CA: Activ Surgical, a digital surgery pioneer, announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 10,925,465 B2 for the company's ActivSight enhanced visualization module. The patent, Activ Surgical's first to be issued in the U.S., protects the form factor of ActivSight, deeming it as novel given its ability to power scopes and other existing hardware in the operating room.

"We are very pleased that the USPTO views the ActivSight visualization module as novel and has granted the company our first U.S. patent," said Tom Calef, Chief Technology Officer, Activ Surgical. "The issuance of this patent is a significant milestone in the development of our global intellectual property portfolio and protects our groundbreaking technology as we prepare for the commercialization of ActivSight later this year. This patent also provides viability, credibility, and assurance of our technology to the 13 major hospital systems around the world that have committed to ActivSight's initial launch in 2021."

ActivSight is the company's proprietary hardware imaging module that will power its first product, ActivINSIGHT. It works dynamically and seamlessly with any installed visualization system to provide real-time intraoperative visual data and images not currently available to surgeons through existing technologies. Together, ActivSight and ActivINSIGHT will offer real-time surgical guidance in the form of previously unavailable visual overlays, including blood flow and perfusion without the need for the injection of dyes, as well as allowing for fluorescing of indocyanine green (ICG) dye. ActivSight has been submitted for FDA clearance and is expected to be commercially available in 2021.